A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy.
Phase of Trial: Phase III
Latest Information Update: 23 Apr 2013
At a glance
- Drugs Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 04 May 2012 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 04 May 2012 Actual patient number is 404 according to ClinicalTrials.gov.